$9 Billion Merger

Directors are selling Juno Therapeutics too cheaply through an unfair process to Celgene, for $87 a share or $9 billion, shareholders <strong><a href="http://www.courthousenews.com/wp-content/uploads/2018/02/Juno.pdf">claim</a></strong> in a federal class action.

SEATTLE — Directors are selling Juno Therapeutics too cheaply through an unfair process to Celgene, for $87 a share or $9 billion, shareholders claim in a federal class action.

Categories / Securities

Subscribe to our free newsletters

Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.